Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)

NCT06491927 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT06491927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06491927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
REGENXBIO Inc.
Phase
Observational
Overall status
Enrolling by invitation
Start date
May 8, 2024
Completion date
December 1, 2029
Enrollment
66 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy